DOPA Decarboxylase Biomarker Improves Diagnosis of Parkinson's and Lewy Body Dementia
Researchers have identified DOPA decarboxylase as a quantitative biomarker in cerebrospinal fluid that improves diagnosis of Parkinson's disease and Lewy body dementia. The protein levels are up to 2.5 times higher in affected patients and can differentiate these conditions from Alzheimer's disease. The discovery provides clinicians with an objective diagnostic tool for conditions that are frequently misdiagnosed due to overlapping symptoms.
An international research consortium has discovered a new quantitative biomarker in cerebrospinal fluid that significantly improves the diagnostic accuracy for Parkinson's disease and Lewy body dementia. The study identifies the protein DOPA decarboxylase—essential for dopamine production—as a highly specific indicator of these diseases, with concentrations in lumbar fluid found to be up to 2.5 times higher in affected patients compared to healthy controls.
The consortium developed two highly sensitive laboratory tests to reliably record the presence of DOPA decarboxylase. The results show that values in the target group are up to two and a half times higher than in healthy control subjects. This difference is clearly measurable compared with patients suffering from Alzheimer's disease, making the test highly specific for differentiating Lewy body disorders from Alzheimer's.
The importance of this discovery for clinical practice is considerable, as dementia with Lewy bodies is often difficult to diagnose correctly at present. Because of the strong overlap of symptoms with other forms of dementia, patients are regularly misdiagnosed. Misdiagnosis can lead to less effective or, in some cases, harmful treatment. The new measurement method provides doctors with an objective tool for determining the right course of action at an early stage.
In addition, a higher concentration of the biomarker correlated directly with the degree of pathological changes in the brain, underlining the biological relevance of the test. The protein DOPA decarboxylase plays a crucial role in the production of dopamine in the brain, and its elevated presence in cerebrospinal fluid directly reflects the pathological changes occurring in the brain's dopamine-producing regions.
Although these results represent a significant step toward everyday application in healthcare, the consortium stresses that further standardization is required. The study was published in Nature Medicine under the title "A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders."